Get started
Mustang Bio, Inc.Mustang Bio, Inc.Mustang Bio, Inc.

Mustang Bio, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

MBIO trade ideas

Continued Bullish: Next $MBIO Target at $5First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, I previously predicted you should shorten $MBIO at $4.02. That was too conservative a bit, but you could have invested in higher growth stocks between then and now, as the most important thing is growth in the shortest time periods. If you had a chance of growing at $0.22+ per share vs. comparatively being able to grow at $0.25+ per share at the same time period, what would you pick? Now, I am saying it is worth it to some (who may not want to diversify in the types of stocks I'm diversifying now) to get $MBIO as a not too risky pick and set it at a $5 sell-off target. Resistance will be there, but the volatility may not be as bad compared to other stocks of similar cap and price in the market. That being said, I rather invest in some other stocks besides this given my risk tolerance and appetite for higher growth periodicals.
NASDAQ:MBIOLong
by gamer456148
2
$MBIO Mustang on Breakout watch Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
NASDAQ:MBIOLong
by DEXWireNews
1
$MBIO Insider buys could turn stock Bullish Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, M
NASDAQ:MBIOLong
by RedHotStocks
MBIO on its Next Breakout: $4.02 Price TargetFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, here is my analysis. Previous wave correlations point that MBIO is on the next wave of a breakout as the previous waves. Many analyst are ranking it a strong buy, and I even decided to replace my ALGN position (which I still believe in) in higher favor of a MBIO position for faster growth during same said time period. They are about to experience a surge in demand in the industry sector they are in, and the target is based off correlations of previous waves and resistance curves. This is another strong trade potential.
NASDAQ:MBIOShort
by gamer456148
108% UPSIDE POTENTIAL ON MUSTANG BIO UPGRADE BY CANTOR Mustang Bio (NASDAQ:MBIO) is up 8.6% after hours following an bullish initiation at Overweight by Cantor, setting a $7s price target, implying 108% upside from today's close. This price target is actually considerable lower that the previous average of $19.50. COMPANY PROFILE Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.
NASDAQ:MBIOLong
by DEXWireNews